TICKERNERD
Menu
AZTAAZTAHealthcare · Medical Instruments & Supplies

AZTA Stock Forecast: Azenta, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$32
+3.86% on the day

The 6 Wall Street analysts covering Azenta, Inc. hold a median 12-month price target of $36 — +10.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 14 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.4B
Ticker Nerd rank
81 / 100
Median analyst target
$36
Analysts covering
6
Revenue$161.2M+12.0% y/y
Operating income−$3.7M
Net income$2.5M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.3%
1M
−4.0%
YTD
−3.7%
1Y
+8.0%
From 52W high
−21.9%
From 52W low
+100.0%
$16
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AZTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Azenta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Value
87
Issuance
82
Quality
75
Volatility
65
Momentum
57
Revisions
45
Growth
44
Size
40

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (44): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (40): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AZTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26AZTAHigh $37Median $36Low $33

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
3 Buy3 Hold0 Sell
Low $33Median $36High $37

The green dot is the last close — the median target sits +10.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
14 Sept 2026NeedhamReiteratesBuy$37
6 Aug 2026Evercore ISI GroupMaintainsOutperform$28 → $35
5 Aug 2026NeedhamMaintainsBuy$33 → $37
6 May 2026NeedhamMaintainsBuy$44 → $33
6 May 2026NeedhamMaintainsBuy—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
17 Mar 2026NeedhamReiteratesBuy—
5 Feb 2026Evercore ISI GroupMaintainsOutperform—
4 Feb 2026JefferiesMaintainsBuy—
4 Feb 2026NeedhamReiteratesBuy—
8 Jan 2026TD CowenMaintainsHold—
5 Jan 2026Evercore ISI GroupUpgradeOutperform—
19 Dec 2025NeedhamMaintainsBuy—
25 Nov 2025Raymond JamesMaintainsOutperform—
21 Nov 2025NeedhamMaintainsBuy—
30 Oct 2025JefferiesUpgradeBuy—
6 Aug 2025Raymond JamesUpgradeOutperform—
5 Aug 2025Evercore ISI GroupMaintainsIn-Line—
8 July 2025Evercore ISI GroupMaintainsIn-Line—
7 May 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AZTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AZTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Azenta, Inc. returned +8.0% against +17.0% for the S&P 500, dividends included.

AZTA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26AZTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AZTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.8%
Analysts raising
2
Analysts cutting
2
Fundamentals

Azenta, Inc. (AZTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.7×

Cheaper than 24% of US stocks

Price / sales
2.3×

Cheaper than 50% of US stocks

Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
34.3×

Cheaper than 8% of US stocks

Growth & margins
Revenue growth (YoY)
12.0%

Higher than 57% of US stocks

Earnings growth (YoY)
12.0%

Higher than 50% of US stocks

Gross margin
44.9%

Higher than 56% of US stocks

Operating margin
−2.3%

Higher than 30% of US stocks

Net margin
−20.0%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−7.0%

Higher than 38% of US stocks

Return on assets
−0.7%

Higher than 41% of US stocks

Dividend yield
1.2%

Higher than 30% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Azenta, Inc. (AZTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Azenta, Inc. has a market value of $1.4B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $613.6M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$122.9M, a −20.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.76.

  • Free cash flow in the twelve months to 30 June 2026: $9.9M.

  • Shares outstanding: 43.8M.

  • Trailing P/E: 31.7×; forward P/E: 54.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.24%, paying out 0% of earnings.

  • Azenta, Inc. employs 2,900 people — $212K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

AZTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
AZTAAzenta, Inc.$1.4B
81
KMTSKestra Medical Technologies Ltd.$1.4B
22
BLFSBioLife Solutions, Inc.$1.7B
91
LMATLeMaitre Vascular, Inc.$1.8B
69
STAASTAAR Surgical Co.$1.2B
73
XRAYDentsply Sirona, Inc.$2.1B
92
NNNNAnbio Biotechnology$879.2M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Azenta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AZTA news & analysis

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

PRNewsWire · 4 Sept 2026positive

Azenta, Inc. announced it has received full repayment, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S. The repayment was received on September 4, 2026.

Why it matters — Full early repayment of the vendor loan resolves a financial obligation tied to the B Medical Systems sale, which may be relevant to Azenta's cash position and balance sheet.

AZENTA ANNOUNCES LEADERSHIP TRANSITION

PRNewsWire · 24 Aug 2026neutral

Azenta announced that current board member Dr. Martin Madaus has been appointed interim President and CEO, following the resignation of John Marotta as executive officer and director. The company reaffirmed its previously announced fourth quarter fiscal 2026 total revenue guidance.

Why it matters — Azenta watchers will focus on how the interim leadership and the resignation of the CEO affect the company's direction and stability.

Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue

Seeking Alpha · 14 Aug 2026neutral

Azenta shares, which hit a multi-year low in May 2026, have since doubled in value, but the article warns that a chart pattern suggests the rally could unwind in the near future. The current financial model supports being long, but that depends on Azenta hitting the targets it has laid out.

Why it matters — A Azenta watcher would care because the piece highlights that the recent sharp rally may not be sustainable and that the stock's outlook hinges on the company meeting its stated financial targets.

Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Azenta, Inc. published the transcript of its Q3 2026 earnings call, as covered by Seeking Alpha. The transcript contains management's discussion from the earnings call.

Why it matters — An AZTA watcher would care because the transcript provides direct insight into management's earnings commentary and discussion of the quarter.

Azenta Q3 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Azenta reported third-quarter fiscal 2026 revenue above its outlook, driven by growth in recurring-revenue businesses and improved Multiomics performance, which helped offset ongoing unevenness in capital equipment markets.

Why it matters — The revenue beat suggests that Azenta's strategic shift toward recurring-revenue streams and its Multiomics segment are gaining traction, which could support more stable financial performance going forward.

FAQ

Frequently asked questions about AZTA stock

What is the AZTA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Azenta, Inc. have a median 12-month price target of $36, with estimates ranging from $33 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZTA stock a buy right now?

Of the 6 analysts covering Azenta, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azenta, Inc. 81 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZTA?

As at 14 Sept 2026, Azenta, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will AZTA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +10.8% from the last close, and Ticker Nerd's factor model ranks Azenta, Inc. 81 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZTA stock forecast for 2030?

No analyst covering Azenta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $37 over the next 12 months.

How has AZTA stock performed over the past year?

Azenta, Inc. returned +8.0% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Azenta, Inc. do?

Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services.

What is the latest news on AZTA?

The most recent item we track (PRNewsWire, 4 Sept 2026): "Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems". Azenta, Inc. announced it has received full repayment, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S. The repayment was received on September 4, 2026.

Company

About Azenta, Inc.

Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repository services that help customers preserve, track, and manage biological and chemical samples across research, clinical development, and commercialization workflows. Azenta also offers sequencing, gene synthesis, and related multiomics services for pharmaceutical, biotechnology, academic, and healthcare customers. Its solutions are used to support drug development, clinical research, advanced therapies, and biospecimen handling, making the company an important provider of infrastructure for sample integrity and data-driven life sciences operations. Azenta is headquartered in Burlington, Massachusetts, and serves a global customer base across North America, Europe, and Asia.

CEO Dr. Martin D. Madaus D.V.M., Ph.D. · 2,900 employees · United States · https://www.azenta.com